News | June 30, 2021
Aarey Drugs and Pharmaceuticals Q4FY21 PAT at Rs. 1.40 Cr
The company has reported total income of Rs.355.43 crores during FY 2020-21
The company has reported total income of Rs.355.43 crores during FY 2020-21
The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
Subscribe To Our Newsletter & Stay Updated
